Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleAstraZeneca has held talks with US rival Bristol Myers Squibb (Reuters)AstraZeneca and US rival Bristol Myers Squibb have reportedly held discussions regarding a potential merger, which could create a pharmaceutical giant valued at over £300 billion. Such a tie-up would establish the world's fourth-largest pharmaceutical company, though sources indicate the deal's progression is uncertain and could face delays or collapse. The proposed merger is expected to face significant regulatory hurdles, particularly from the Trump administration's antitrust authorities, who have sought to increase domestic investment. Cambridge-based AstraZeneca, with a market value of approximately £196 billion, is seeking to expand its presence in the US, while New York-listed BMS is valued at around £133 billion. An analyst noted that despite AstraZeneca's previous statements about not needing mergers and acquisitions, a deal with BMS could face challenges due to their large, overlapping cancer divisions. In fullAstraZeneca in talks over £300bn mega-merger with US rival – reportsMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
AstraZeneca ‘in talks to create £300bn pharmaceutical giant’
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleAstraZeneca has held talks with US rival Bristol Myers Squibb (Reuters)AstraZeneca and US rival Bristol Myers Squibb have reportedly held discussions regarding a potential merger, which could create a pharmaceutical giant valued at over £300 billion. Such a tie-up would establish the world's fourth-largest pharmaceutical company, though sources indicate the deal's progression is uncertain and could face delays or collapse. The proposed merger is expected to face significant regulatory hurdles, particularly from the Trump administration's antitrust authorities, who have sought to increase domestic investment. Cambridge-based AstraZeneca, with a market value of approximately £196 billion, is seeking to expand its presence in the US, while New York-listed BMS is valued at around £133 billion. An analyst noted that despite AstraZeneca's previous statements about not needing mergers and acquisitions, a deal with BMS could face challenges due to their large, overlapping cancer divisions. In fullAstraZeneca in talks over £300bn mega-merger with US rival – reportsMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
AstraZeneca and Bristol Myers Squibb in talks for £300 billion merger creating the fourth-largest pharma, facing Trump antitrust risks. The deal signals pharma M&A consolidation amid stricter compliance governance reshaping tech stack investments in life sciences.
